Because BRD4 inhibitors and HHT could downregulate MYC through different pathways, and the downregulation of WNT/β‐catenin by HHT presumably could help overcome resistance to BRD4 inhibitors, we attempted to combine a novel BRD4 inhibitor ACC010 and HHT in AML cells. The gene discussed is BRD4; the disease is acute myeloid leukemia.